How Research Peptides Are Synthesised: SPPS, Recombinant, and Hybrid Methods

Almost every research peptide on the market was made by one of three methods: solid-phase peptide synthesis, recombinant expression, or a hybrid of the two. Understanding which method produced your compound — and how rigorously it was purified afterwards — is part of judging supplier quality.

Solid-phase peptide synthesis (SPPS)

The dominant method for peptides under approximately 50 residues. Developed by Bruce Merrifield (Nobel Prize in Chemistry, 1984), SPPS anchors the C-terminal amino acid to a polymer resin and adds amino acids one at a time toward the N-terminus. Each cycle deprotects the growing chain, couples the next amino acid, and washes away excess reagents. After the final residue is added, the peptide is cleaved from the resin and side-chain protecting groups are removed.

Recombinant expression

For larger peptides, or when complex post-translational modifications are required, peptides are expressed in microbial or mammalian cell culture. E. coli is the most common host for non-glycosylated peptides; yeast or mammalian cells are used when glycosylation matters. The peptide is then extracted, purified by chromatography, and characterised.

Hybrid approaches

The GLP-1 class is typically produced by hybrid methods: the core peptide is recombinantly expressed, then chemically modified to attach the fatty-acid linker. This combines the efficiency of biological expression with the precision of chemical conjugation.

Purification

Regardless of synthesis method, the crude product is rarely usable as-is. Reversed-phase HPLC is the standard purification technique for research peptides. The peptide is loaded onto a hydrophobic stationary phase and eluted with a gradient of organic solvent (acetonitrile in water with trifluoroacetic acid). The main peak is collected; impurities elute earlier or later. The recovered peptide is lyophilised for stability.

Why purity matters

Impurities at the 1–2% level can be deleterious: truncated sequences may bind receptors with different affinity, oxidation products may alter pharmacology, and residual coupling reagents may interfere with downstream assays. The 98% minimum purity standard for research peptides is not arbitrary; it reflects the threshold at which contaminants typically stop confounding experiments.

Verification

Purity by HPLC and identity by mass spectrometry are the two non-negotiables. Pillar Research compounds are verified by an independent third-party Australian laboratory. See our guide on how to read a peptide COA for what good verification documentation looks like.